NCT05940272Recruiting
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 3 Jul 2023
- Start date
- 3 Jul 2023
- Primary completion date
- 3 Jul 2028
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT05940272
What you commit to
- Study type: Interventional
- Planned participants: 48
- From 3 Jul 2023 to the primary completion date, 3 Jul 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Per medical record or self-report, receiving hospice care at the time of enrollment
Other illness
- Per self-report, planning to leave the cancer center in the next 12 months
- Patients
Other
- Providers
- Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
- Per research staff judgment and/or self-report, too ill or weak to complete study procedures
Who the study is looking for
- Providers
- Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)
- Patients
- Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
- Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
- Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
- Self-identify as Black and/or White
- Per medical record, 18 years of age or older
- Per self-report, fluent in English\*\*
- Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
- How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
- What is your preferred language for healthcare? (must respond English)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only) Coordinator of this site? Confirm its status | New York | United States | Not yet recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.